Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kane

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Nature|May 20, 2022
Compatibility rules of human enhancer and promoter sequencesDrew T Bergman, Thouis R Jones, Vincent Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignanciesEric H Rubin, Dinesh P de Alwis, Isabelle Pouliquen, et al.
Cancer Gene Therapy|June 22, 2019
Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinomaDaniella E Portal, Robert E Weiss, Malgorzata Wojtowicz, et al.
Environmental Science & Technology Letters|July 14, 2025
Responding after Hurricane Helene: Rapidly Estimating Impacts to Environmental Health Services in North CarolinaKelsey J Pieper, Edward Beighley, C Nathan Jones, et al.
Nature Genetics|December 1, 2019
Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbationsCharles P Fulco, Joseph Nasser, Thouis R Jones, et al.
Journal of the National Cancer Institute|November 21, 2017
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric CancerAnshuman Panda, Janice M Mehnert, Kim M Hirshfield, et al.
Neuro-Oncology|January 14, 2017
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomasYu Sun, John A Alberta, Catherine Pilarz, et al.
Nature|April 8, 2021
Genome-wide enhancer maps link risk variants to disease genesJoseph Nasser, Drew T Bergman, Charles P Fulco, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2020
Forest and woodland replacement patterns following drought-related mortalityEnric Batllori, Francisco Lloret, Tuomas Aakala, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Nature|May 20, 2022
Compatibility rules of human enhancer and promoter sequencesDrew T Bergman, Thouis R Jones, Vincent Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignanciesEric H Rubin, Dinesh P de Alwis, Isabelle Pouliquen, et al.
Cancer Gene Therapy|June 22, 2019
Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinomaDaniella E Portal, Robert E Weiss, Malgorzata Wojtowicz, et al.
Environmental Science & Technology Letters|July 14, 2025
Responding after Hurricane Helene: Rapidly Estimating Impacts to Environmental Health Services in North CarolinaKelsey J Pieper, Edward Beighley, C Nathan Jones, et al.
Nature Genetics|December 1, 2019
Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbationsCharles P Fulco, Joseph Nasser, Thouis R Jones, et al.
Journal of the National Cancer Institute|November 21, 2017
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric CancerAnshuman Panda, Janice M Mehnert, Kim M Hirshfield, et al.
Neuro-Oncology|January 14, 2017
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomasYu Sun, John A Alberta, Catherine Pilarz, et al.
Nature|April 8, 2021
Genome-wide enhancer maps link risk variants to disease genesJoseph Nasser, Drew T Bergman, Charles P Fulco, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2020
Forest and woodland replacement patterns following drought-related mortalityEnric Batllori, Francisco Lloret, Tuomas Aakala, et al.
Pageof 7